Since acquiring the rights to its proprietary, non-insecticide diol technology in the 1990s, EctoPharma has successfully brought this head lice product through all stages of research & development to the point that it is market-ready. In 2010, the company successfully concluded a marketing out-licensing agreement with Thornton & Ross covering the commercialisation of the product in the EU. Thornton & Ross, European leaders in the head lice market, who launched the product on to the market as "Hedrin Treat & Go" in July 2011.
Currently, EctoPharma is actively seeking a marketing partner for the North American and Chinese markets.
KindaPed™ has the potential to be effective in both human and animal applications.